Abstract: Infants aged 90 days or younger with fever are frequently evaluated in the pediatric emergency department. Physical examination findings and individual laboratory investigations are not reliable to differentiate benign viral infections from serious bacterial infections in febrile infants. Clinical prediction models were developed more than 25 years ago and have high sensitivity but relatively low specificity to identify bacterial infections in febrile infants. Newer laboratory investigations such as C-reactive protein and procalcitonin have favorable test characteristics compared with traditional laboratory studies such as a white blood cell count. These novel biomarkers have not gained widespread acceptance because of lack of robust prospectively collected data, varying thresholds to define positivity, and differing inclusion criteria across studies. However, C-reactive protein and procalcitonin, when combined with other patient characteristics in the step-by-step approach, have a high sensitivity for detection of serious bacterial infection. The RNA biosignatures are a novel biomarker under investigation for detection of bacterial infection in febrile infants. 
TARGET AUDIENCE
This continuing medical education activity is intended for physicians, physician assistants, and nurse practitioners who care for pediatric patients in the outpatient, emergency department, or inpatient settings.
LEARNING OBJECTIVES
After completion of this article, the reader should be able to:
• Summarize the changing epidemiology of serious bacterial infections and invasive bacterial infections in febrile infants aged 90 days or younger in the vaccine era.
• Discuss the strengths and weaknesses of previously established clinical prediction models for febrile infants in the vaccine era.
• Describe the current literature on novel biomarkers including C-reactive protein, procalcitonin, and RNA biosignatures for identification of bacterial infection in febrile infants.
F ever accounts for 10% to 20% of all pediatric emergency department visits. 1, 2 Although viruses account for the majority of infections, up to 8% to 12.5% of all febrile infants aged 90 days or younger will have a serious bacterial infection (SBI). 3 Among these infants, urinary tract infections predominate. However, 1% to 2% will have an invasive bacterial infection (IBI), ie, bacteremia and bacterial meningitis. Delayed diagnosis of IBIs is associated with increased morbidity and mortality, although there is a paucity of outcome data for these infections in young infants. [4] [5] [6] [7] It is difficult to differentiate benign viral infections from the more serious IBIs in febrile infants aged 90 days or younger based on symptoms or individual laboratory tests alone. 8, 9 Therefore, clinical prediction models were developed in the 1980s and early 1990s to help guide the practitioner's medical decision-making regarding the diagnostic workup and therapeutic interventions. [10] [11] [12] These models include historical features, physical examination findings, and laboratory data such as white blood cell (WBC) count, absolute band count or band-to-neutrophil ratio, urinalysis (UA), and cerebrospinal fluid WBC count to risk stratify febrile infants into high-risk and low-risk groups for SBI (Table 1) Although there has been ongoing work to examine the reproducibility and validity of these risk-stratification algorithms, no single approach is uniformly used. 8 In the past 2 decades, incorporation of newer vaccines into the routine immunization schedule for infants in the United States has changed the epidemiology of bacterial infections in infants. 13, 14 However, the impact of these vaccines on the diagnostic test performance of the clinical prediction models remains largely unstudied. We must also evaluate new laboratory tools that can be incorporated into these prediction models to improve their diagnostic performance or that may better serve as stand-alone biomarkers for detection of SBI and IBI.
Epidemiology of Fever Without a Source in the Vaccine Era
The rate of IBI in previously healthy older infants and children has decreased dramatically since the implementation of routine vaccination for Haemophilus influenzae type B (HiB) and pneumococcus. 15, 16 Among young infants, an inverse relationship between infant age and SBI prevalence has been demonstrated with a decline in SBI from 21.6% in the first week of life to 12.1% in the fourth week of life, 17 with a lower prevalence approximately 8% after age 1 month. 18 The prevalence of IBI also has an inverse relationship with age in the vaccine era. 18 Watt et al 13 reported an IBI prevalence of 5.1% in infants aged 0 to 30 days, 3.9% in aged 31 to 60 days, and 0.9% in aged 61 to 90 days. In addition, the overall prevalence of bacterial meningitis is low in the 90-days-or-younger population, at 0.6% to 0.9%. 4, 13 Haemophilus influenzae type B and pneumococcus were causes of IBI before routine vaccination. [11] [12] [13] [14] 16, 19 Although HiB is exceedingly rare in the vaccine era, the incidence of pneumococcus has also declined due to herd immunity. 20 Now, SBIs and IBIs are most commonly caused by Escherichia coli, group B streptococcus (GBS), Staphylococcus aureus, Klebsiella species, and, uncommonly, Enterococcus. 4, 14, 21, 22 The GBS prevalence has had a recent decline in infants aged 90 days or younger, likely secondary to routine perinatal prophylaxis. 23, 24 In addition, Listeria monocytogenes is now rarely identified as a pathogen in febrile infants with IBI. 21, 22, 25, 26 Therefore, traditionally used empiric antibiotic coverage, in particular ampicillin, should be reassessed in the era of vaccines and perinatal prophylaxis. With a changing epidemiology of SBI/IBI, we must also reevaluate the diagnostic accuracy of our clinical prediction models. Few studies have evaluated the diagnostic accuracy of previously established clinical prediction models in the post-HiB and post-pneumococcal vaccine era. One study conducted in the Bronx, NY, performed a reappraisal of the Rochester and Philadelphia criteria. Both criteria demonstrated high sensitivity of 97% (95% confidence interval [CI], 89%-100%) for identification of SBI when these previously established clinical prediction models were applied to febrile infants aged 56 days or younger. 8, 27 However, the test characteristics for the identification of IBI were unclear because of the single center design of this study and relatively small numbers of IBI. 8, 27 Critically, these prediction models are primarily designed to have high sensitivity for identification of bacterial infections that have high potential for morbidity and mortality. Therefore, in optimizing sensitivity at the expense of specificity, the prediction models identify most true-positive cases of SBI. However, many infants classified as high-risk will not have an SBI. The aforementioned study from the Bronx reported that both the Rochester and Philadelphia criteria had low specificity of 37% (95% CI, 30%-44%) with the application of these previously established clinical prediction models in the vaccine era. 8, 27 Are There New Diagnostic Tools That Can Be Incorporated Into Clinical Prediction Models to Improve Their Diagnostic Performance?
Novel diagnostic tests with improved sensitivity and specificity for the detection of SBI and IBI have the potential to reduce unnecessary lumbar puncture, hospitalization, antibiotic exposure, and iatrogenic harm among febrile infants. Although many studies have evaluated the diagnostic accuracy of C-reactive protein (CRP) and procalcitonin (PCT) for the identification of SBI or IBI in children younger than 36 months, the following sections will focus on studies that specifically evaluated diagnostic accuracy of CRP, PCT, and RNA biosignatures in infants aged 90 days or younger fever without source (FWS).
C-Reactive Protein
C-reactive protein is an acute-phase reactant synthesized in the liver within 4 to 6 hours after tissue injury and that peaks at 36 hours. 28 Many studies have demonstrated superior, albeit variable, test characteristics of CRP compared with WBC for the detection of bacterial infection (Tables 2, 3) . [29] [30] [31] [32] [33] 38 The heterogeneity in the study designs (retrospective vs prospective), case definitions, prevalence of SBI and IBI, sample sizes, and lack of uniformity of cutoff values has made the interpretation of these findings challenging. However, CRP has consistently demonstrated higher specificity than WBC count for SBI and IBI, often at the expense of lower sensitivity. [29] [30] [31] [32] [33] 38 Although Milcent et al 33 reported the highest sensitivity of 77% (95% CI, 66-86) for detection of SBI with a cutoff value of 20 mg/L, this sensitivity is still low for detection of bacterial infection. Although the specificity of CRP is likely superior to WBC count in detecting SBI/IBI, the summative data from these studies suggest that CRP is likely not sufficient to serve as a stand-alone test in detecting SBI/IBI in infants aged 90 days or younger with FWS. However, making formal recommendations based on these studies is difficult because of variability in SBI definition, lack of raw data on IBI, differing inclusion criteria between studies, differing clinical settings between studies, and varying results (Tables 2, 3 ).
Procalcitonin
Procalcitonin is the protein prohormone of calcitonin that is released by the liver and mononuclear cells 4 hours after tissue injury and that peaks 6 hours after tissue injury with a sustained peak level for 8 to 24 hours. 39 Previous studies reported PCT as being more sensitive and specific for SBI and IBI than WBC, although a majority of patients in these studies were older infants and children (aged up to 36 mo). 40, 41 Overall, in studies limited to febrile infants aged 90 days or younger with FWS, PCT has demonstrated favorable test characteristics compared with WBC and CRP for detection of both SBI and IBI (Tables 2, 3) . [29] [30] [31] [33] [34] [35] 38 However, in addition to the heterogeneity of the design of these studies and of the prevalence of SBI and IBI, the biggest challenge to interpretation is the varying performance characteristics of PCT based on the threshold used to define positivity. Maniaci et al demonstrated the highest sensitivity of PCT in detection of SBI at a level of 0.13 ng/mL. However, the specificity at this level was low ( Table 2) . 34 The most consistent cutoff value used has been 0.5 ng/mL, which has high specificity but inadequate sensitivity for the detection of SBI. In the largest prospective study to date, Milcent et al reported a sensitivity of 60% (95% CI, 48-72) for SBI and 85% (95% CI, 62-97) for IBI at a cutoff value of 0.5 ng/mL, with a specificity of 85% for both SBI and IBI. A lower threshold value to 0.3 ng/mL improved the sensitivity with only marginal reduction in specificity (Tables 2, 3 ). However, the small number of IBIs in this study resulted in wide confidence limits around the point estimate for sensitivity. 33 In aggregate, these studies suggest that PCT is superior to CRP and WBC for the detection of SBI and IBI, but the exact threshold value to maximize the combination of sensitivity and specificity remains uncertain (Tables 2, 3 ).
New Prediction Models That Incorporate CRP and PCT
These studies demonstrate that a single laboratory test alone cannot reliably identify or exclude the diagnosis of SBI or IBI among febrile infants aged 90 days or younger. However, recent investigations have incorporated the use of these newer diagnostic tests into clinical algorithms to optimize the identification of SBI and IBI among febrile infants in the vaccine era. The "Lab score" assigns points based on results of urine dipstick, PCT, and CRP. A score of 3 points or higher defines a population at higher risk of bacterial infection (Table 4) . 42 In the original validation of the score, a sensitivity of 94% (95% CI, 74%-99%) and specificity of 78% (95% CI, 64%-87%) was observed for the detection of SBI in children aged 36 months or younger. 42 However, external validation studies focusing on well-appearing infants younger than 3 months using this prediction model have reported high specificity but low sensitivity for detection of SBI and IBI (Tables 2, 3) . 36, 37 Most recently, Gomez et al 42 validated the "Step-by-Step" approach for risk stratification of infants aged 90 days or younger with FWS. This approach uses age, clinical appearance, urine dipstick, PCT, CRP, and absolute neutrophil count (ANC) in a stepwise fashion to determine which infants are high-, intermediate-, and low-risk for SBI and IBI (Table 4) . Gomez et al 42 prospectively compared the Step-by-Step approach, Lab score and Rochester criteria in infants aged 90 days or younger with FWS and reported that the Step-by-Step approach had the highest sensitivity for detection of IBI (92.0% [95% CI, 84.3%-96.0%]), and although similar to the low-risk criteria, the specificity was low (Table 3 ). In comparison, the Lab score was very specific but its low sensitivity limits its use as a screening test for IBI (Table 3) . 37 The RNA Biosignatures This novel diagnostic tool has been gaining interest as a more precise method to differentiate viral infections from bacterial infections by analyzing the transcriptional biosignatures of RNA in host leukocytes in response to a clinically undifferentiated infection (Fig. 1) . 43 Initial research in hospitalized children (aged 14 d-16 y) reported that RNA biosignatures could differentiate bacterial infections from viral infections with up to 95% accuracy in the inpatient setting. 44 Mahajan et al demonstrated that RNA biosignatures could also distinguish bacterial from viral infections in infants aged 60 days or younger with a sensitivity of 87% (95% CI, 73%-95%) and a specificity of 89% (95% CI, 81%-93%). 45 Although these initial results are promising, the wide confidence limits related to the small sample size and lack of a rapid turnaround time may limit their widespread use. Future translational research should seek to validate the initial studies in a large-enough sample to reliably evaluate the performance of this testing in a generalizable fashion. In addition, the logistics of sample collection, storage, and processing time warrants further investigation before widespread clinical implementation.
CONCLUSIONS
Although the epidemiology and prevalence of SBI and IBI in infants aged 90 days or younger has changed in the vaccine era, previously developed clinical prediction models have retained their high sensitivity for detection of bacterial infection, although specificity remains low. Advances in technology have allowed novel laboratory biomarkers to be incorporated into clinical prediction models to improve their diagnostic performance. Although neither CRP nor PCT have adequate diagnostic test characteristics to be used as a stand-alone test to identify bacterial infection in febrile infants, they offer promise when combined with other clinical and laboratory findings in the Step-by-Step approach. Large prospective studies are needed to evaluate the performance, cost, feasibility, and outcomes of using these newer approaches in the management of the febrile infant. In addition, future studies that evaluate the use of RNA biosignatures for the identification of bacterial infections among febrile infants are warranted.
